Rob Koremans

2017

In 2017, Rob Koremans earned a total compensation of $5.1M as Former President and CEO, Global Specialty at Teva Pharmaceutical Industries.

Compensation breakdown

Option Awards$833,361
Salary$783,215
Stock Awards$1,666,644
Other$1,807,975
Total$5,091,195

Koremans received $1.8M in other compensation, accounting for 36% of the total pay in 2017.

Koremans also received $833.4K in option awards, $783.2K in salary and $1.7M in stock awards.

Rankings

In 2017, Rob Koremans' compensation ranked 1,837th out of 14,666 executives tracked by ExecPay. In other words, Koremans earned more than 87.5% of executives.

ClassificationRankingPercentile
All
1,837
out of 14,666
88th
Division
Manufacturing
613
out of 5,772
89th
Major group
Chemicals And Allied Products
163
out of 2,075
92nd
Industry group
Drugs
118
out of 1,731
93rd
Industry
Pharmaceutical Preparations
91
out of 1,333
93rd
Source: SEC filing on April 25, 2018.

Koremans' colleagues

We found nine more compensation records of executives who worked with Rob Koremans at Teva Pharmaceutical Industries in 2017.

2017

Kåre Schultz

Teva Pharmaceutical Industries

Chief Executive Officer

2017

Yitzhak Peterburg

Teva Pharmaceutical Industries

Chief Executive Officer

2017

Carlo de Notaristefani

Teva Pharmaceutical Industries

Executive Vice President, Global Operations

2017

Michael Hayden

Teva Pharmaceutical Industries

Chief Scientific Officer

2017

Eyal Desheh

Teva Pharmaceutical Industries

Chief Financial Officer

2017

Hafrun Fridriksdottir

Teva Pharmaceutical Industries

Executive Vice President, Global Research and Development

2017

Erez Vigodman

Teva Pharmaceutical Industries

Chief Executive Officer

2017

Mark Sabag

Teva Pharmaceutical Industries

Executive Vice President, Global Human Resources

2017

Michael McClellan

Teva Pharmaceutical Industries

Chief Financial Officer

You may also like